Challenges of repurposing tetracyclines for the treatment of Alzheimer’s and Parkinson’s disease
The DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.
Abstract
The novel antibiotic-exploiting strategy in the treatment of Alzheimer's (AD) and Parkinson's (PD) disease has emerged as a potential breakthrough in the field. The research in animal AD/PD models provided evidence on the antiamyloidogenic, anti-inflammatory, antioxidant and antiapoptotic activity of tetracyclines, associated with cognitive improvement. The neuroprotective effects of minocycline and doxycycline in animals initiated investigation of their clinical efficacy in AD and PD patients which led to inconclusive results and additionally to insufficient safety data on a long-standing doxycycline and minocycline therapy in these patient populations. The safety issues should be considered in two levels; in AD/PD patients (particularly antibiotic-induced alteration of gut microbiota and its consequences), and as a world-wide threat of development of bacterial resistance to these antibiotics posed by a fact that AD and PD are widespread incurable diseases which require daily administered long-lasting antibiotic therapy. Recently proposed subantimicrobial doxycycline doses should be thoroughly explored for their effectiveness and long-term safety especially in AD/PD populations. Keeping in mind the antibacterial activity-related far-reaching undesirable effects both for the patients and globally, further work on repurposing these drugs for a long-standing therapy of AD/PD should consider the chemically modified tetracycline compounds tailored to lack antimicrobial but retain (or introduce) other activities effective against the AD/PD pathology. This strategy might reduce the risk of long-term therapy-related adverse effects (particularly gut-related ones) and development of bacterial resistance toward the tetracycline antibiotic agents but the therapeutic potential and desirable safety profile of such compounds in AD/PD patients need to be confirmed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Generally, although promising, two main concerns remain about the use of antibiotics in PD treatment: (i) antibiotics can kill some specific microbial populations leading to intestinal dysbiosis and neurological dysfunction and (ii) their prolonged and widespread intake would favor antibiotic resistance [213,300,301].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [301]
In the citing paper
“Generally, although promising, two main concerns remain about the use of antibiotics in PD treatment: (i) antibiotics can kill some specific microbial populations leading to intestinal dysbiosis and neurological dysfunction and (ii) their prolonged and widespread intake would favor antibiotic resistance [213,300,301].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [301]
Citations
Cites
1 retracted
Kim, D. S., Ko, B., Ryuk, J. A., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082900 · Cited by 37
RetractedApoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853 · cited 1×
“There are two main apoptotic pathways (the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway) which converge on the execution pathway initiated by the cleavage of caspase-3 and subsequently resulting in the irreversible processes leading towards cell death (Elmore 2007).”
BackgroundCryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Oxidative stress, aging, and diseases
Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s158513 · Cited by 3,979 · cited 1×
“2019) and epigenetic changes like methylation (Bradley-Whitman and Lovell 2013) but also because of the age-related decrease in brain insulin level and IR expression (Akintola and van Heemst 2015) and vulnerability to oxidative stress (Liguori et al. 2018).”
BackgroundGut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Dorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Research works printed but not linked: 8
- Beauduy CEWL (2018) Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, & oxazolidinones. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw Hill-Education, New York, pp 815–825
- Erekat NS (2018) Apoptosis and its role in Parkinson’s disease. In: Stoker TB, Greenland JC (eds) Parkinson’s disease: pathogenesis and clinical aspects, chapter 4. Codon Publications, Brisbane
- Forloni G, Salmona M, Marcon G et al (2012) Tetracyclines and prion infectivity. Infect Disord Drug Targets 9(1):23–30. https://doi.org/10.2174/1871526510909010023 · DOI · Paper page
- Holmes C (2017) Inflammation in Alzheimer’s disease. In: Ames D, O’Brien JT, Burns A (eds) Dementia, 5th edn. CRC Press, Boca Raton
- Ian C, Marilyn R (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65(3):232–260. https://doi.org/10.1128/MMBR.65.2.232 · doi:10.1128/mmbr.65.2.232
- Kempuraj D, Thangavel R, Natteru PA et al (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1(1):1003
- Perdue BE, Standiford HC (1999) Tetracyclines. In: Yu VL, Merigan TC, Barriere SL (eds) Antimicrobial therapy and Vaccines. Williams and Wilkins, Baltimore, p 981
- Tong M, Dong M, De La Monte SM (2009) Brain Insulin-like growth factor and neurotrophin resistance in parkinson’s disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis 16(3):585–599. https://doi.org/10.3233/JAD-2009-0995.Brain · doi:10.3233/jad-2009-0995.brain
Cited by
Qin, J., Ma, Z., Chen, X., & Shu, S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1103416 · Cited by 207
“The fact that AD/PD patients (especially the changes of intestinal flora caused by antibiotics and their consequences), as well as AD and PD are universal incurable diseases that require long-term antibiotic treatment every day, constitutes a worldwide threat of bacterial resistance to these antibiotics (147).”
BackgroundVaresi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 56
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 42
Serebrovska, Z. O., Xi, L., Tumanovska, L. V., Shysh, A. M., Goncharov, S. V., Khetsuriani, M., Kozak, T. O., Pashevin, D. O., Dosenko, V., Virko, S. V., et al. (2022) · Life · doi:10.3390/life12030432 · Cited by 34
“Recent studies have underscored an anti-inflammatory and/or antioxidant therapeutic approach to reducing the rate of development of the main AD symptoms [25,26].”
Background
Metadata
- Authors
- Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M.
- Affiliations
- University Hospital Centre Zagreb (HR)
- Venue
- Journal of Neural Transmission
- Published
- 2022-01-04
- Volume
- 129
- Issue
- 5-6
- Pages
- 773-804
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W4205398889
- Cited by
- 36
- References
- 261
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 7 · 2023: 7 · 2022: 4
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Regional Development Fund (GA KK01.1.1.01.0007)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- tetracycline, drug repurposing, Alzheimer's disease, Parkinson's disease, minocycline, doxycycline, antibiotic resistance, gut microbiota, neuroprotection, chemically modified tetracyclines
- MeSH terms
- Alzheimer Disease, Animals, Anti-Bacterial Agents, Doxycycline, Humans, Minocycline, Parkinson Disease, Tetracycline, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges of repurposing tetracyclines for the treatment of Alzheimer’s and Parkinson’s disease. https://app.cochat.ai/papers/10.1007/s00702-021-02457-2
- The paper
- Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022). Challenges of repurposing tetracyclines for the treatment of Alzheimer’s and Parkinson’s disease. Journal of Neural Transmission. https://doi.org/10.1007/s00702-021-02457-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.